Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted therapies that are more effective and tolerable than traditional ...
Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...
Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...
For decades, despite many attempts, KRAS-mutated lung cancer did not have a targeted therapy available. The first KRAS-targeted agent called sotorasib was approved in 2021. While the new approval ...
This includes achieving cancer remission, shrinking a tumor before surgery, killing remaining cancer cells after surgery, or relieving lung cancer symptoms when the disease cannot be treated.
Combination Treatment Improves Response to Immunotherapy for Lung Cancer Sep. 25, 2024 — Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow ...